Rituximab-induced late onset neutropenia in newly-diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism

American Journal of Hematology

Volumn 85, Issue 10, 2010, Pages 810-812

  Li, Szu Chin ^a   Chen, Yi Chun ^a   Evens, Andrew M ^b   Lee, Ching Chih ^a,c   Liao, Hui Fen ^d   Yu, Chi Chia ^a   Tung, Ya Ting ^a,d   Su, Yu Chieh ^a,c  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b NORTHWESTERN UNIVERSITY   (United States)

^c TZU CHI UNIVERSITY   (Taiwan)

^d NATIONAL CHIAYI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; FC RECEPTOR; FCGR3A PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; COHORT ANALYSIS; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; LATE ONSET NEUTROPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; BLOOD; CHEMICALLY INDUCED; COMPARATIVE STUDY; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; IMMUNOLOGY; INCIDENCE; LYMPHOMA, B-CELL; MIDDLE AGED; PHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TIME;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INCIDENCE; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEUTROPENIA; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IGG; TIME FACTORS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED;

EID: 77957653353     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21818     Document Type: Article

References (19)

1. Nitta E, Izutsu K, Sato T, et al. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: A single-institution study. Ann Oncol 2007;18:364-369.
2. Dunleavy K, Tay K, Wilson WH. Rituximab-associated neutropenia. Semin Hematol 2010;47:180-186.
3. McLaughlin P. Late-onset neutropenia following rituximab. Leuk Lymphoma 2006; 47:965-966.
4. Fukuno K, Tsurumi H, Ando N, et al. Late-onset neutropenia in patients treated with rituximab for non-Hodgkin's lymphoma. Int J Hematol 2006;84:242-247. (Pubitemid 44619246)
5. Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. N Engl J Med 2003;348:2691-2694; discussion 2691-2694.
6. Chaiwatanatorn K, Lee N, Grigg A, Filshie R, et al. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol 2003;121:913-918. (Pubitemid 36760311)
7. Lemieux B, Tartas S, Traulle C, et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2004;33:921-923.
8. Osborne JM, Chacko GW, Brandt JT, Anderson CL. Ethnic variation in frequency of an allelic polymorphism of human Fc gamma RIIA determined with allele specific oligonucleotide probes. J Immunol Methods 1994;173:207-217. (Pubitemid 124014392)
9. Satoh T, Kobayashi M, Kaneda M, et al. Genotypical classification of neutrophil Fc gamma receptor III by polymerase chain reaction-single-strand conformation polymorphism. Blood 1994;83:3312-3315. (Pubitemid 24979714)
10. Reilly AF, Norris CF, Surrey S, et al. Genetic diversity in human Fc receptor II for immunoglobulin G: Fc gamma receptor IIA ligand-binding polymorphism. Clin Diagn Lab Immunol 1994;1:640-644. (Pubitemid 2164279)
11. Weng WK, Negrin RS, Lavori P, Horning SJ. Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma. J Clin Oncol 2010;28:279-284.
12. Tesfa D, Gelius T, Sander B, et al. Late-onset neutropenia associated with rituximab therapy: Evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Med Oncol 2008. p 374-379.
13. Lai GG, Lim ST, Tao M, et al. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma. Am J Hematol 2009;84:414-417.
14. Cattaneo C, Spedini P, Casari S, et al. Delayed-onset peripheral blood cytopenia after rituximab: Frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 2006;47:1013-1017. (Pubitemid 44102962)
15. Marotte H, Paintaud G, Watier H, Miossec P. Rituximab-related late-onset neutropenia in a patient with severe rheumatoid arthritis. Ann Rheum Dis 2008;67:893-894. (Pubitemid 351829397)
16. Rios-Fernandez R, Gutierrez-Salmeron MT, Callejas-Rubio JL, et al. Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases. Br J Dermatol 2007;157:1271-1273. (Pubitemid 350119793)
17. Stamatopoulos K, Papadaki T, Pontikoglou C, et al. Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia. Leukemia 2008;22:1446-1449. (Pubitemid 352006092)
18. Terrier B, Ittah M, Tourneur L, et al. Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. Haematologica 2007;92:e20-e23.
19. Leppers-van de Straat FG, van der Pol WL, Jansen MD, et al. A novel PCR-based method for direct Fc gamma receptor IIIa (CD16) allotyping. J Immunol Methods 2000;242:127-132.